Valvular & structural heart disease
Stroke reduction by cerebral embolic protection devices in transcatheter aortic valve implantation: a systematic review and Bayesian meta-analysis
Pooled result · Disabling strokeResult — go to the resultMedian relative risk 0.56 95% CrI 0.28–1.19Authors' conclusion
There is a high probability of a beneficial CEP treatment effect, but this is unlikely to be clinically relevant.
Study context
- Population
- Patients undergoing transcatheter aortic valve implantation (TAVI)
- Participants
- 3,996 patients7 RCTs
- Comparison
- Cerebral embolic protection (CEP) vs standard treatment during TAVI
- CEPn = 2,126
- Controln = 1,870reference
- Outcome
- Disabling stroke
Methodological detailsvague prior (principal), informed literature-based priors (secondary)
- Vague prior (principal)
- Informed literature-based priors (secondary)
Pooled result
As reported in the abstract
Median relative risk
0.56
95% CrI 0.28–1.19
CEPvs Control
median RR 0.56 (95% CrI 0.28–1.19)
- Posterior probability of any benefit
- 94.4%
- Probability of clinically relevant effect (MCID 1.1% ARD, NNT 91), vague and informed priors
- 0-0.1%
Further pooled results
- Results robust across multiple sensitivity analyses
Original publication
Stroke reduction by cerebral embolic protection devices in transcatheter aortic valve implantation: a systematic review and Bayesian meta-analysis. Heart. Published 23 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →